This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Zosano Pharma Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Anahtar bilgiler

-5.0%

Kazanç büyüme oranı

75.3%

EPS büyüme oranı

Medical Equipment Sektör Büyümesi	4.3%
Gelir büyüme oranı	86.7%
Özkaynak getirisi	-392.7%
Net Marj	-8,375.1%
Son Kazanç Güncellemesi	31 Mar 2022

Yakın geçmiş performans güncellemeleri

Recent updates

Gelir ve Gider Dağılımı

Zosano Pharma nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

DB:0ZP Gelir, gider ve kazançlar (USD Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri
31 Mar 22	1	-55	11
31 Dec 21	1	-30	11
30 Sep 21	1	-31	11
30 Jun 21	1	-31	11
31 Mar 21	0	-33	11
31 Dec 20	0	-33	11
30 Sep 20	0	-34	12
30 Jun 20	0	-35	12
31 Mar 20	0	-37	12
31 Dec 19	0	-38	12
30 Sep 19	0	-39	11
30 Jun 19	0	-37	10
31 Mar 19	0	-37	10
31 Dec 18	0	-35	9
30 Sep 18	0	-33	9
30 Jun 18	0	-32	8
31 Mar 18	0	-30	8
31 Dec 17	0	-29	8
30 Sep 17	0	-29	8
30 Jun 17	0	-29	8
31 Mar 17	0	-29	8
31 Dec 16	0	-30	8
30 Sep 16	0	-30	8
30 Jun 16	0	-31	7
31 Mar 16	0	-32	7
31 Dec 15	0	-28	6

Kaliteli Kazançlar: 0ZP is currently unprofitable.

Büyüyen Kar Marjı: 0ZP is currently unprofitable.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: 0ZP is unprofitable, and losses have increased over the past 5 years at a rate of 5% per year.

Büyüme Hızlandırma: Unable to compare 0ZP's earnings growth over the past year to its 5-year average as it is currently unprofitable

Kazançlar vs. Sektör: 0ZP is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (-37.9%).

Özkaynak Getirisi

Yüksek ROE: 0ZP has a negative Return on Equity (-392.74%), as it is currently unprofitable.

This company is no longer active

Zosano Pharma Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

First quarter 2022 earnings released: US$7.87 loss per share (vs US$2.73 loss in 1Q 2021)

Zosano Pharma Corporation Reports Impairment Charges for the First Quarter Ended March 31, 2022

Recent updates

Emergex USA Corporation completed the acquisition of Substantially all assets of Zosano Pharma Corporation for $1 million.

Emergex USA Corp. agreed to acquire Substantially all assets of Zosano Pharma Corporation (OTCPK:ZSAN.Q) for $1.3 million.

Motion for Case Conversion Filed for Zosano Pharma Corporation

Motion for Asset Sale Filed by Zosano Pharma Corporation

Zosano Pharma Corporation to Delist from Nasdaq

Zosano Pharma Corporation Filed for Bankruptcy

First quarter 2022 earnings released: US$7.87 loss per share (vs US$2.73 loss in 1Q 2021)

Joseph “Jay” P. Hagan Resigns as Director of the Board of Directors of Zosano Pharma Corporation

Zosano Pharma Corporation Reports Impairment Charges for the First Quarter Ended March 31, 2022

Steven A. Elms Tenders His Resignation as Director of the Board of Directors of Zosano Pharma Corporation

Zosano Pharma Corporation Receives a Response Letter from the U.S. Food and Drug Administration with Regard to the Company’s January 18, 2022 Resubmission of the 505(b)(2) New Drug Application for M207

Zosano Pharma Corporation has completed a Composite Units Offering in the amount of $15.375 million.

Zosano Pharma Corporation has completed a Composite Units Offering.

Zosano Pharma Corporation Resubmits its M207 (Zolmitriptan Transdermal Microneedle System) 505(B)(2) New Drug Application to the U.S. Food and Drug Administration

Zosano Pharma Announces Publication of Clinical Data Demonstrating Comparable Immunogenicity of A Trivalent Influenza Vaccine Formulated on Its Transdermal Microneedle System Versus an Intramuscular Injection of the Vaccine At A Higher Dose

Zosano Pharma Corporation Announces Publication of Clinical Data Regarding the Long-Term Use of Qtrypta for the Treatment of Acute Migraine in the Journal of Headache and Pain

Zosano Pharma Confirms Plan to Move Forward with Pharmacokinetic Study Following Protocol Review by FDA

Revenue in line with expectations

Zosano Pharma Corporation Announces John Walker, Chairman of the Board of Directors to Retire from the Board

Zosano Pharma Confirms NDA Resubmission Strategy Following Type A Meeting Minutes from FDA

New 90-day high: €1.26

Zosano Pharma Corporation Announces NDA Resubmission Plans Following Type A Meeting with FDA

New 90-day high: €0.90

New 90-day high: €0.64

Zosano Pharma Requests Type A Meeting with the Fda to Review Resubmission Plans for Qtrypta™ New Drug Application

Bragar Eagel & Squire, P.C. Reminds Investors of Class Action Lawsuit Filed Against Zosano Pharma Corporation

Pomerantz LLP Reminds Shareholders with Losses on Their Investment in Zosano Pharma Corporation of Class Action Lawsuit and Upcoming Deadline

New 90-day low: €0.21

Rosen Announces Filing of Securities Class Action Lawsuit Against Zosano Pharma Corporation

New 90-day low: €0.54

New 90-day low: €0.64

Zosano Pharma Corporation Receives Discipline Review Letter from the U.S. Food and Drug Administration in Connection with the Qtrypta

Zosano Pharma Corporation has completed a Follow-on Equity Offering in the amount of $20.782018 million.

New 90-day high - €1.11

Zosano Pharma Corporation(NasdaqCM:ZSAN) dropped from Russell Microcap Growth Index

Gelir ve Gider Dağılımı

Kazanç ve Gelir Geçmişi

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Özkaynak Getirisi

Varlık Getirisi

Kullanılan Sermaye Getirisi

Geçmişte güçlü performans gösteren şirketleri keşfedin